• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Castle Biosciences Reports Second Quarter 2024 Results

    8/5/24 4:05:00 PM ET
    $CSTL
    Medical Specialities
    Health Care
    Get the next $CSTL alert in real time by email

    Q2 2024 revenue increased 74% over Q2 2023 to $87 million

    Q2 2024 total test reports increased 49% over Q2 2023

    Raising full-year 2024 revenue guidance to $275-300 million from $255-265 million

    Conference call and webcast today at 4:30 p.m. ET

    Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2024.

    "We achieved another quarter of exceptional performance, thanks to the hard work of our talented team and strength of our innovative test portfolio," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "We were especially pleased with the substantial top-line growth as well as growth in test report volumes across our therapeutic areas."

    "Regarding our DecisionDx®-SCC test, we were also pleased to see the publication of our first study evaluating the use of DecisionDx-SCC to guide adjuvant radiation therapy (ART) recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC). This study, which is the largest study to evaluate the effectiveness of ART in SCC, found that the DecisionDx-SCC test can identify patients who are considering ART under traditional clinicopathologic risk features and have a low likelihood of metastasis and a low likelihood of a receiving a clinical benefit from ART – thus enabling deferral of radiation therapy and avoidance of complications and associated impacts on the patient's quality of life. This study was published in the American Society for Radiation Oncology's flagship journal, International Journal of Radiation Oncology, Biology, Physics (also known as the Red Journal).

    "Regarding our TissueCypher® Barrett's Esophagus test, the American Gastroenterological Association (AGA) recently recognized in its Clinical Practice Guideline that there is a high-risk subset of non-dysplastic Barrett's esophagus patients who may benefit from early intervention with endoscopic eradication therapy (EET) and importantly, acknowledged that tissue-based biomarker testing, including the tissue systems pathology test (i.e., TissueCypher, also known as TSP-9) can help identify these patients.

    "We believe we are well-positioned for near- and long-term success, supported by the potential for continued growth across our portfolio, as well as by our robust balance sheet and proven track record of strong execution. I am proud of what we have accomplished, and we will continue to work to operate with speed and agility to deliver value to patients, clinicians and stockholders alike."

    Second Quarter Ended June 30, 2024, Financial and Operational Highlights

    • Revenues were $87.0 million, a 74% increase compared to $50.1 million in the second quarter of 2023. Included in revenue for the period were revenue adjustments related to tests delivered in prior periods. These prior period revenue adjustments for the quarter were $0.4 million of net positive revenue adjustments, compared to $0.1 million of net negative revenue adjustments for the same period in 2023.
    • Adjusted Revenues, which exclude the effects of revenue adjustments related to tests delivered in prior periods, were $86.6 million, a 72% increase compared to $50.2 million for the same period in 2023.
    • Delivered 25,102 total test reports in the second quarter of 2024, an increase of 49% compared to 16,820 in the same period of 2023:
      • DecisionDx®-Melanoma test reports delivered in the quarter were 9,585, compared to 8,597 in the second quarter of 2023, an increase of 11%.
      • DecisionDx-SCC test reports delivered in the quarter were 4,277, compared to 2,681 in the second quarter of 2023, an increase of 60%.
      • MyPath® Melanoma test reports delivered in the quarter were 1,099, compared to 953 in the second quarter of 2023, an increase of 15%.
      • TissueCypher Barrett's Esophagus test reports delivered in the quarter were 4,782, compared to 1,447 in the second quarter of 2023, an increase of 230%.
      • IDgenetix® test reports delivered in the quarter were 4,903, compared to 2,681 in the second quarter of 2023, an increase of 83%.
      • DecisionDx®-UM test reports delivered in the quarter were 456, compared to 461 in the second quarter of 2023, a decrease of 1%.
    • Gross margin was 81%, and Adjusted Gross Margin was 83%, compared to 74% and 78%, respectively, for the same periods in 2023.
    • Net cash provided by operations was $24.0 million, compared to $3.8 million net cash used in operations for the same period in 2023.
    • Net income, which includes non-cash stock-based compensation expense of $13.2 million, was $8.9 million, compared to a net loss of $(18.8) million for the same period in 2023.
    • Adjusted EBITDA was $21.5 million, compared to $(5.3) million for the same period in 2023.

    Six Months Ended June 30, 2024, Financial and Operational Highlights

    • Revenues were $160.0 million, a 74% increase compared to $92.2 million during the same period in 2023. Included in revenue for the period were revenue adjustments related to tests delivered in prior periods. These prior period revenue adjustments for the six months ended June 30, 2024, were $1.0 million of net positive revenue adjustments, compared to $1.7 million of net negative revenue adjustments for the same period in 2023.
    • Adjusted Revenues, which exclude the effects of revenue adjustments related to tests delivered in prior periods, were $159.0 million, a 69% increase compared to $93.9 million for the same period in 2023.
    • Delivered 45,990 total test reports in the six months ended June 30, 2024, an increase of 45% compared to 31,736 in the same period of 2023:
      • DecisionDx-Melanoma test reports delivered in the six months ended June 30, 2024, were 17,969, compared to 16,180 for the same period in 2023, an increase of 11%.
      • DecisionDx-SCC test reports delivered in the six months ended June 30, 2024, were 7,854, compared to 5,092 for the same period in 2023, an increase of 54%.
      • MyPath Melanoma test reports delivered in the six months ended June 30, 2024, were 2,097, compared to 1,933 for the same period in 2023, an increase of 8%.
      • TissueCypher Barrett's Esophagus test reports delivered in the six months ended June 30, 2024, were 8,211, compared to 2,830 for the same period in 2023, an increase of 190%.
      • IDgenetix test reports delivered in the six months ended June 30, 2024, were 8,981, compared to 4,831 for the same period in 2023, an increase of 86%.
      • DecisionDx-UM test reports delivered in the six months ended June 30, 2024, were 878, compared to 870 for the same period in 2023, an increase of 1%.
    • Gross margin for the six months ended June 30, 2024, was 79%, and Adjusted Gross Margin was 82%.
    • Net cash provided by operations was $17.2 million, compared to $29.2 million net cash used in operations for the same period in 2023.
    • Net income for the six months ended June 30, 2024, which includes non-cash stock-based compensation expense of $25.9 million, was $6.4 million, compared to a net loss of $(48.0) million for the same period in 2023.
    • Adjusted EBITDA for the six months ended June 30, 2024, was $32.1 million, compared to $(20.4) million for the same period in 2023.

    Cash, Cash Equivalents and Marketable Investment Securities

    As of June 30, 2024, the Company's cash, cash equivalents and marketable investment securities totaled $259.7 million.

    2024 Outlook

    Based upon revenue generated through June 30, 2024, the Company is increasing its guidance for anticipated total revenue in 2024 to between $275–300 million, compared to the previously provided guidance of between $255–265 million.

    Second Quarter and Recent Accomplishments and Highlights

    Dermatology

    • DecisionDx-SCC: The Company announced the publication of a study in the International Journal of Radiation Oncology, Biology, Physics (Red Journal) demonstrating the ability of the DecisionDx-SCC test to identify high-risk SCC patients who are likely to benefit from ART to reduce metastatic disease progression, as well as high-risk patients who are unlikely to benefit from ART and who, therefore, may consider deferring treatment. This study is the single largest study ever conducted to evaluate the effectiveness of ART in patients diagnosed with SCC and demonstrates the impact of the test in guiding decision-making for recommending ART. See the Company's news release from May 29, 2024, for more information.
    • DecisionDx-SCC: The Company also shared new data that supported the utility of DecisionDx-SCC in patients with high-risk SCC tumors located on the head and neck at the 56th American College of Mohs Surgery (ACMS) Annual Meeting in Phoenix. Data presented demonstrated that testing with DecisionDx-SCC significantly increased the prediction accuracy of metastatic events, when used alone and when combined with National Comprehensive Cancer Network (NCCN) guidelines, Brigham and Women's Hospital (BWH) staging or American Joint Committee on Cancer Staging Manual, 8th Edition (AJCC8) staging, to better guide risk-aligned patient care decisions regarding metastatic surveillance or the use of adjuvant treatments like radiation. See the Company's news release from May 3, 2024, for more information.
    • DecisionDx-Melanoma: The Company presented new data relating to its DecisionDx-Melanoma test at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, demonstrating the test's ability to identify patients with localized cutaneous melanoma at the highest risk of metastasis to the central nervous system (CNS). Specifically, the study showed that DecisionDx-Melanoma can identify patients with earlier-stage melanoma who have a higher risk of CNS metastasis within the first three years post-diagnosis. These higher-risk patients may benefit from more frequent imaging surveillance to identify CNS metastases earlier to improve patient survival. See the Company's news release from May 30, 2024, for more information.

    Gastroenterology

    • The Company announced that the AGA published new clinical practice guidelines for EET to treat Barrett's esophagus (BE) and prevent its progression to esophageal adenocarcinoma. These guidelines recognized that there is a high-risk subset of patients with non-dysplastic BE (NDBE) who may benefit from early intervention with EET and acknowledged the role that tissue-based biomarkers, including TissueCypher, can play in identifying these patients. See the Company's news release from June 24, 2024, for more information.
    • The Company also shared three abstracts supporting the ability of its TissueCypher test to predict risk of progression to esophageal cancer in patients with BE at the Digestive Disease Week (DDW) 2024 Annual Meeting in Washington, D.C. The data that was shared further expanded the substantial clinical evidence supporting TissueCypher and its ability to improve the care that BE patients receive. See the Company's news release from May 14, 2024, for more information.

    Mental Health

    • The Company was selected as the winner of the "Best Overall Mental Health Solution" award in the eighth annual MedTech Breakthrough Awards program for its IDgenetix pharmacogenomic (PGx) test. The MedTech Breakthrough Awards honor excellence and recognize innovation, hard work and success in a range of health and medical technology categories, attracting thousands of nominations from over 18 countries across the world. See the Company's news release from May 10, 2024, for more information.

    Uveal Melanoma

    • The Company announced results from the largest prospective study to date of patients with uveal melanoma, titled "15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)," confirming the prognostic accuracy of the DecisionDx-UM test and providing the first prospective validation of Preferentially Expressed Antigen in Melanoma (PRAME) status as a risk refinement tool when considered in the context of a Class 1 or Class 2 DecisionDx-UM result. The study data demonstrated that together, these two tests can guide more precise and risk-aligned decision-making for patients with UM, including referrals, intensity of imaging surveillance and eligibility for ongoing clinical trials. See the Company's news release from May 8, 2024, and the published paper in the Journal of Clinical Oncology for more information.

    Corporate

    • The Company announced that its founder, president and chief executive officer, Derek Maetzold, was named by Ernst & Young LLP (EY) as an Entrepreneur Of The Year® 2024 Gulf South Award winner. Now in its 38th year, Entrepreneur Of The Year is the preeminent competitive awards program that celebrates entrepreneurs and leaders of high-growth companies who disrupt markets, revolutionize sectors and have a transformational impact on lives. See the Company's news release from June 14, 2024, for more information.

    Conference Call and Webcast Details

    Castle Biosciences will hold a conference call on Monday, August 5, 2024, at 4:30 p.m. Eastern time to discuss its second quarter 2024 results and provide a corporate update.

    A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/952012940 or via the webcast link on the Investor Relations page of the Company's website, https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. An archive of the webcast will be available on the Company's website until August 26, 2024.

    To access the live conference call via phone, please dial 833 470 1428 from the United States, or +1 404 975 4839 internationally, at least 10 minutes prior to the start of the call, using the conference ID 802518.

    There will be a brief Question & Answer session following management commentary.

    Use of Non-GAAP Financial Measures (UNAUDITED)

    In this release, we use the metrics of Adjusted Revenues, Adjusted Gross Margin and Adjusted EBITDA, which are non-GAAP financial measures and are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). Adjusted Revenues and Adjusted Gross Margin reflect adjustments to GAAP net revenues to exclude net positive and/or net negative revenue adjustments recorded in the current period associated with changes in estimated variable consideration related to test reports delivered in previous periods. Adjusted Gross Margin further excludes acquisition-related intangible asset amortization. Adjusted EBITDA excludes from net income (loss): interest income, interest expense, income tax expense (benefit), depreciation and amortization expense, stock-based compensation expense, change in fair value of contingent consideration and acquisition related transaction costs.

    We use Adjusted Revenues, Adjusted Gross Margin and Adjusted EBITDA internally because we believe these metrics provide useful supplemental information in assessing our revenue and operating performance reported in accordance with GAAP, respectively. We believe that Adjusted Revenues, when used in conjunction with our test report volume information, facilitates investors' analysis of our current-period revenue performance and average selling price performance by excluding the effects of revenue adjustments related to test reports delivered in prior periods, since these adjustments may not be indicative of the current or future performance of our business. We believe that providing Adjusted Revenues may also help facilitate comparisons to our historical periods. Adjusted Gross Margin is calculated using Adjusted Revenues and therefore excludes the impact of revenue adjustments related to test reports delivered in prior periods, which we believe is useful to investors as described above. We further exclude acquisition-related intangible asset amortization in the calculation of Adjusted Gross Margin. We believe that excluding acquisition-related intangible asset amortization may facilitate gross margin comparisons to historical periods and may be useful in assessing current-period performance without regard to the historical accounting valuations of intangible assets, which are applicable only to tests we acquired rather than internally developed. We believe Adjusted EBITDA may enhance an evaluation of our operating performance because it excludes the impact of prior decisions made about capital investment, financing, investing and certain expenses we believe are not indicative of our ongoing performance. However, these non-GAAP financial measures may be different from non-GAAP financial measures used by other companies, even when the same or similarly titled terms are used to identify such measures, limiting their usefulness for comparative purposes.

    These non-GAAP financial measures are not meant to be considered in isolation or used as substitutes for net revenues, gross margin or net income (loss) reported in accordance with GAAP; should be considered in conjunction with our financial information presented in accordance with GAAP; have no standardized meaning prescribed by GAAP; are unaudited; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that we may exclude for purposes of these non-GAAP financial measures, and we may in the future cease to exclude items that we have historically excluded for purposes of these non-GAAP financial measures. Likewise, we may determine to modify the nature of adjustments to arrive at these non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measure as used by us in this press release and the accompanying reconciliation tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. Accordingly, investors should not place undue reliance on non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of this release.

    About Castle Biosciences

    Castle Biosciences (NASDAQ:CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

    Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe, atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

    DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. These forward-looking statements include, but are not limited to, statements concerning our expectations regarding: (i) our 2024 total revenue guidance of $275-300 million; (ii) the potential of our tests to improve patient outcomes, including increased survival; (iii) our continued commercial momentum in 2024; (iv) our ability to continue to develop evidence to support the clinical utility of our tests; and (v) our ability to achieve near- and long-term success and the continued growth of our portfolio. The words "anticipate," "can," "could," "expect," "goal," "may," "plan" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: our assumptions or expectations regarding continued reimbursement for our DecisionDx-SCC test at the current rate and reimbursement for our other products and subsequent coverage decisions, our estimated total addressable markets for our products and product candidates and the related expenses, capital requirements and potential needs for additional financing, the anticipated cost, timing and success of our product candidates, and our plans to research, develop and commercialize new tests and our ability to successfully integrate new businesses, assets, products or technologies acquired through acquisitions, the effects of macroeconomic events and conditions, including inflation and monetary supply shifts, labor shortages, liquidity concerns at, and failures of, banks and other financial institutions or other disruptions in the banking system or financing markets and recession risks, supply chain disruptions, outbreaks of contagious diseases and geopolitical events (such as the ongoing Israel-Hamas War and Ukraine-Russia conflict), among others, on our business and our efforts to address its impact on our business; subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results discussed in this press release, including with respect to the tests discussed in this press release; our planned installation of additional equipment and supporting technology infrastructures and implementation of certain process efficiencies may not enable us to increase the future scalability of our TissueCypher Test; actual application of our tests may not provide the aforementioned benefits to patients; our newer gastroenterology and mental health franchises may not contribute to the achievement of our long-term financial targets as anticipated; and the risks set forth under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, each filed or to be filed with the SEC, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.

     

    CASTLE BIOSCIENCES, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (UNAUDITED)

    (in thousands, except per share data)

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    NET REVENUES

    $

    87,002

     

     

    $

    50,138

     

     

    $

    159,976

     

     

    $

    92,175

     

    OPERATING EXPENSES

     

     

     

     

     

     

     

    Cost of sales (exclusive of amortization of acquired intangible asset)

     

    14,519

     

     

     

    11,058

     

     

     

    28,413

     

     

     

    21,240

     

    Research and development

     

    14,136

     

     

     

    13,308

     

     

     

    27,945

     

     

     

    27,701

     

    Selling, general and administrative

     

    51,088

     

     

     

    44,681

     

     

     

    99,583

     

     

     

    91,443

     

    Amortization of acquired intangible asset

     

    2,247

     

     

     

    2,248

     

     

     

    4,494

     

     

     

    4,470

     

    Total operating expenses, net

     

    81,990

     

     

     

    71,295

     

     

     

    160,435

     

     

     

    144,854

     

    Operating income (loss)

     

    5,012

     

     

     

    (21,157

    )

     

     

    (459

    )

     

     

    (52,679

    )

    Interest income

     

    3,144

     

     

     

    2,399

     

     

     

    6,140

     

     

     

    4,735

     

    Interest expense

     

    (270

    )

     

     

    (3

    )

     

     

    (284

    )

     

     

    (7

    )

    Income (loss) before income taxes

     

    7,886

     

     

     

    (18,761

    )

     

     

    5,397

     

     

     

    (47,951

    )

    Income tax (benefit) expense

     

    (1,034

    )

     

     

    16

     

     

     

    (989

    )

     

     

    30

     

    Net income (loss)

    $

    8,920

     

     

    $

    (18,777

    )

     

    $

    6,386

     

     

    $

    (47,981

    )

     

     

     

     

     

     

     

     

    Earnings (loss) per share:

     

     

     

     

     

     

     

    Basic

    $

    0.32

     

     

    $

    (0.70

    )

     

    $

    0.23

     

     

    $

    (1.80

    )

    Diluted

    $

    0.31

     

     

    $

    (0.70

    )

     

    $

    0.22

     

     

    $

    (1.80

    )

     

     

     

     

     

     

     

     

    Weighted-average shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    27,646

     

     

     

    26,733

     

     

     

    27,566

     

     

     

    26,670

     

    Diluted

     

    28,738

     

     

     

    26,733

     

     

     

    28,542

     

     

     

    26,670

     

     

     

     

     

     

     

     

     

    Stock-Based Compensation Expense

    Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands):

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Cost of sales (exclusive of amortization of acquired intangible assets)

    $

    1,401

     

    $

    1,202

     

    $

    2,715

    $

    2,474

    Research and development

     

    2,637

     

     

     

    2,486

     

     

     

    5,266

     

     

    5,073

     

    Selling, general and administrative

     

    9,141

     

     

     

    9,161

     

     

     

    17,873

     

     

    18,827

     

    Total stock-based compensation expense

    $

    13,179

     

     

    $

    12,849

     

     

    $

    25,854

     

    $

    26,374

     

     

    CASTLE BIOSCIENCES, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

    (UNAUDITED)

    (in thousands)

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Net income (loss)

    $

    8,920

     

     

    $

    (18,777

    )

     

    $

    6,386

     

     

    $

    (47,981

    )

    Other comprehensive (loss) income:

     

     

     

     

     

     

     

    Net unrealized (loss) gain on marketable investment securities

     

    (61

    )

     

     

    (8

    )

     

     

    (308

    )

     

     

    237

     

    Comprehensive income (loss)

    $

    8,859

     

     

    $

    (18,785

    )

     

    $

    6,078

     

     

    $

    (47,744

    )

     

    CASTLE BIOSCIENCES, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

     

     

    June 30,

    2024

     

    December 31,

    2023

    ASSETS

    (unaudited)

     

     

    Current Assets

     

     

     

    Cash and cash equivalents

    $

    85,572

     

     

    $

    98,841

     

    Marketable investment securities

     

    174,116

     

     

     

    144,258

     

    Accounts receivable, net

     

    45,988

     

     

     

    38,302

     

    Inventory

     

    8,013

     

     

     

    7,942

     

    Prepaid expenses and other current assets

     

    6,716

     

     

     

    6,292

     

    Total current assets

     

    320,405

     

     

     

    295,635

     

    Long-term accounts receivable, net

     

    1,125

     

     

     

    1,191

     

    Property and equipment, net

     

    38,638

     

     

     

    25,433

     

    Operating lease assets

     

    11,621

     

     

     

    12,306

     

    Goodwill and other intangible assets, net

     

    112,840

     

     

     

    117,335

     

    Other assets – long-term

     

    2,683

     

     

     

    1,440

     

    Total assets

    $

    487,312

     

     

    $

    453,340

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

    Current Liabilities

     

     

     

    Accounts payable

    $

    9,540

     

     

    $

    10,268

     

    Accrued compensation

     

    21,239

     

     

     

    28,945

     

    Operating lease liabilities

     

    1,226

     

     

     

    1,137

     

    Other accrued and current liabilities

     

    7,449

     

     

     

    7,317

     

    Total current liabilities

     

    39,454

     

     

     

    47,667

     

    Long-term debt

     

    10,008

     

     

     

    —

     

    Noncurrent operating lease liabilities

     

    13,645

     

     

     

    14,173

     

    Noncurrent finance lease liabilities

     

    312

     

     

     

    25

     

    Deferred tax liability

     

    —

     

     

     

    206

     

    Total liabilities

     

    63,419

     

     

     

    62,071

     

    Stockholders' Equity

     

     

     

    Common stock

     

    28

     

     

     

    27

     

    Additional paid-in capital

     

    636,022

     

     

     

    609,477

     

    Accumulated deficit

     

    (211,985

    )

     

     

    (218,371

    )

    Accumulated other comprehensive (loss) income

     

    (172

    )

     

     

    136

     

    Total stockholders' equity

     

    423,893

     

     

     

    391,269

     

    Total liabilities, and stockholders' equity

    $

    487,312

     

     

    $

    453,340

     

     

    CASTLE BIOSCIENCES, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (UNAUDITED)

    (in thousands)

     

     

    Six Months Ended

    June 30,

     

     

    2024

     

     

     

    2023

     

    OPERATING ACTIVITIES

     

     

     

    Net income (loss)

    $

    6,386

     

     

    $

    (47,981

    )

    Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

     

     

     

    Depreciation and amortization

     

    6,688

     

     

     

    5,932

     

    Stock-based compensation expense

     

    25,854

     

     

     

    26,374

     

    Deferred income taxes

     

    (1,542

    )

     

     

    13

     

    Accretion of discounts on marketable investment securities

     

    (3,422

    )

     

     

    (2,282

    )

    Other

     

    83

     

     

     

    213

     

    Change in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    (7,620

    )

     

     

    (7,978

    )

    Prepaid expenses and other current assets

     

    (294

    )

     

     

    158

     

    Inventory

     

    (71

    )

     

     

    (2,141

    )

    Operating lease assets

     

    678

     

     

     

    (469

    )

    Other assets

     

    143

     

     

     

    (80

    )

    Accounts payable

     

    (1,650

    )

     

     

    3,071

     

    Operating lease liabilities

     

    (432

    )

     

     

    958

     

    Accrued compensation

     

    (7,706

    )

     

     

    (7,060

    )

    Other accrued and current liabilities

     

    68

     

     

     

    2,047

     

    Net cash provided by (used in) operating activities

     

    17,163

     

     

     

    (29,225

    )

     

     

     

     

    INVESTING ACTIVITIES

     

     

     

    Purchases of property and equipment

     

    (14,381

    )

     

     

    (7,373

    )

    Proceeds from sale of property and equipment

     

    7

     

     

     

    8

     

    Purchases of marketable investment securities

     

    (113,194

    )

     

     

    (86,438

    )

    Proceeds from maturities of marketable investment securities

     

    86,450

     

     

     

    95,000

     

    Net cash (used in) provided by investing activities

     

    (41,118

    )

     

     

    1,197

     

     

     

     

     

    FINANCING ACTIVITIES

     

     

     

    Proceeds from exercise of common stock options

     

    73

     

     

     

    184

     

    Payment of employees' taxes on vested restricted stock units

     

    (1,089

    )

     

     

    (848

    )

    Proceeds from contributions to the employee stock purchase plan

     

    1,749

     

     

     

    1,688

     

    Repayment of principal portion of finance lease liabilities

     

    (47

    )

     

     

    (70

    )

    Proceeds from issuance of term debt

     

    10,000

     

     

     

    —

     

    Net cash provided by financing activities

     

    10,686

     

     

     

    954

     

     

     

     

     

    NET CHANGE IN CASH AND CASH EQUIVALENTS

     

    (13,269

    )

     

     

    (27,074

    )

    Beginning of period

     

    98,841

     

     

     

    122,948

     

    End of period

    $

    85,572

     

     

    $

    95,874

     

    CASTLE BIOSCIENCES, INC.

    Reconciliation of Non-GAAP Financial Measures (UNAUDITED)

    The table below presents the reconciliation of adjusted revenues and adjusted gross margin, which are non-GAAP financial measures. See "Use of Non-GAAP Financial Measures (UNAUDITED)" above for further information regarding the Company's use of non-GAAP financial measures.

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    (in thousands)

     

     

     

     

     

     

     

    Adjusted revenues

     

     

     

     

     

     

     

    Net revenues (GAAP)

    $

    87,002

     

     

    $

    50,138

     

     

    $

    159,976

     

     

    $

    92,175

     

    Revenue associated with test reports delivered in prior periods

     

    (363

    )

     

     

    88

     

     

     

    (959

    )

     

     

    1,705

     

    Adjusted revenues (Non-GAAP)

    $

    86,639

     

     

    $

    50,226

     

     

    $

    159,017

     

     

    $

    93,880

     

     

     

     

     

     

     

     

     

    Adjusted gross margin

     

     

     

     

     

     

     

    Gross margin (GAAP)1

    $

    70,236

     

     

    $

    36,832

     

     

    $

    127,069

     

     

    $

    66,465

     

    Amortization of acquired intangible assets

     

    2,247

     

     

     

    2,248

     

     

     

    4,494

     

     

     

    4,470

     

    Revenue associated with test reports delivered in prior periods

     

    (363

    )

     

     

    88

     

     

     

    (959

    )

     

     

    1,705

     

    Adjusted gross margin (Non-GAAP)

    $

    72,120

     

     

    $

    39,168

     

     

    $

    130,604

     

     

    $

    72,640

     

     

     

     

     

     

     

     

     

    Gross margin percentage (GAAP)2

     

    80.7

    %

     

     

    73.5

    %

     

     

    79.4

    %

     

     

    72.1

    %

    Adjusted gross margin percentage (Non-GAAP)3

     

    83.2

    %

     

     

    78.0

    %

     

     

    82.1

    %

     

     

    77.4

    %

    ______________________

    1.

    Calculated as net revenues (GAAP) less the sum of cost of sales (exclusive of amortization of acquired intangible assets) and amortization of acquired intangible assets.

    2.

    Calculated as gross margin (GAAP) divided by net revenues (GAAP).

    3.

    Calculated as adjusted gross margin (Non-GAAP) divided by adjusted revenues (Non-GAAP).

    The table below presents the reconciliation of adjusted EBITDA, which is a non-GAAP financial measure. See "Use of Non-GAAP Financial Measures (UNAUDITED)" above for further information regarding the Company's use of non-GAAP financial measures.

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    (in thousands)

     

     

     

     

     

     

     

    Adjusted EBITDA

     

     

     

     

     

     

     

    Net income (loss)

    $

    8,920

     

     

    $

    (18,777

    )

     

    $

    6,386

     

     

    $

    (47,981

    )

    Interest income

     

    (3,144

    )

     

     

    (2,399

    )

     

     

    (6,140

    )

     

     

    (4,735

    )

    Interest expense

     

    270

     

     

     

    3

     

     

     

    284

     

     

     

    7

     

    Income tax (benefit) expense

     

    (1,034

    )

     

     

    16

     

     

     

    (989

    )

     

     

    30

     

    Depreciation and amortization expense

     

    3,348

     

     

     

    3,040

     

     

     

    6,688

     

     

     

    5,932

     

    Stock-based compensation expense

     

    13,179

     

     

     

    12,849

     

     

     

    25,854

     

     

     

    26,374

     

    Adjusted EBITDA (Non-GAAP)

    $

    21,539

     

     

    $

    (5,268

    )

     

    $

    32,083

     

     

    $

    (20,373

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240805085135/en/

    Get the next $CSTL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CSTL

    DatePrice TargetRatingAnalyst
    12/14/2023$25.00Buy
    Guggenheim
    1/5/2023$54.00Sector Outperform
    Scotiabank
    1/7/2022$59.00Overweight
    Stephens & Co.
    11/9/2021$85.00 → $75.00Outperform
    SVB Leerink
    7/14/2021$80.00 → $85.00Outperform
    SVB Leerink
    More analyst ratings

    $CSTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Castle Biosciences with a new price target

      Guggenheim initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $25.00

      12/14/23 6:54:55 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Scotiabank initiated coverage on Castle Biosciences with a new price target

      Scotiabank initiated coverage of Castle Biosciences with a rating of Sector Outperform and set a new price target of $54.00

      1/5/23 7:53:37 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Stephens & Co. initiated coverage on Castle Biosciences with a new price target

      Stephens & Co. initiated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $59.00

      1/7/22 5:42:05 AM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture

      FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces program: a third consecutive national Healthcare Industry Top Workplaces award, with Castle ranking third among other recognized companies in its size bracket; a fourth consecutive regional Arizona Top Workplaces award from AZ Central; and consecutive national Top Workplaces Culture Excellence awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & Values. "Being recognized as a Top Workplace, ye

      7/17/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

      FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

      7/14/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 14, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 66 employees covering an aggregate of 135,978 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting c

      6/19/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    SEC Filings

    See more
    • SEC Form 144 filed by Castle Biosciences Inc.

      144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      6/27/25 6:11:51 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)

      5/23/25 4:39:01 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Castle Biosciences Inc.

      SCHEDULE 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      5/12/25 3:55:49 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres. & Chief Exec. Officer Maetzold Derek J sold $458,293 worth of shares (22,576 units at $20.30), decreasing direct ownership by 7% to 69,683 units (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      7/1/25 4:05:26 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Director Cole G Bradley converted options into 8,673 shares, increasing direct ownership by 65% to 21,964 units (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      5/23/25 5:01:17 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Director Bradbury Daniel converted options into 8,673 shares (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      5/23/25 4:19:15 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

      The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit

      4/30/24 4:30:00 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

      -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

      10/23/23 8:00:00 AM ET
      $CSTL
      $EQ
      $ICPT
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

      SAN DIEGO, May 26, 2021  /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful

      5/26/21 12:42:00 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      11/14/24 4:40:39 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      11/13/24 6:44:33 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      7/8/24 4:32:39 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Financials

    Live finance-specific insights

    See more
    • Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

      FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

      7/14/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences Reports First Quarter 2025 Results

      Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025. "We are pleased with the exceptional start to the year, marked by continued growth in test report volum

      5/5/25 4:06:00 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

      FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/787806709, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

      4/14/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care